NKGen Biotech announced that its CEO, Dr. Paul Y. Song, will present the company's lead drug candidate, troculeucel, at the 2026 BIOCHINA Global Forum in Seoul. Troculeucel is an investigational natural killer cell therapy currently in Phase 2 trials for Alzheimer's disease and is being explored for other neurodegenerative diseases like ALS, FTD, and Parkinson's. The presentation will also cover regulatory opportunities in China and potential collaborations with Chinese pharmaceutical companies. This event highlights NKGen's efforts to expand its global network and advance its innovative therapies.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
